Fikrig E, Telford S R, Wallich R, Chen M, Lobet Y, Matuschka F R, Kimsey R B, Kantor F S, Barthold S W, Spielman A, Flavell R A
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520.
J Exp Med. 1995 Jan 1;181(1):215-21. doi: 10.1084/jem.181.1.215.
Diversity and mutations in the genes for outer surface proteins (Osps) A and B of Borrelia burgdorferi sensu lato (B. burgdorferi), the spirochetal agent of Lyme disease, suggests that a monovalent OspA or OspB vaccine may not provide protection against antigenically variable naturally occurring B. burgdorferi. We now show that OspA or OspB immunizations protect mice from tick-borne infection with heterogeneous B. burgdorferi from different geographic regions. This result is in distinct contrast to in vitro killing analyses and in vivo protection studies using syringe injections of B. burgdorferi as the challenge inoculum. Evaluations of vaccine efficacy against Lyme disease and other vector-borne infections should use the natural mode of transmission and not be predicated on classification systems or assays that do not rely upon the vector to transmit infection.
莱姆病的螺旋体病原体——伯氏疏螺旋体狭义种（Borrelia burgdorferi sensu lato，B. burgdorferi）外表面蛋白（Osp）A和B基因的多样性及突变表明，单价OspA或OspB疫苗可能无法抵御抗原性多变的天然存在的B. burgdorferi。我们现在表明，用OspA或OspB免疫可保护小鼠免受来自不同地理区域的异质性B. burgdorferi经蜱传播的感染。这一结果与使用注射器注射B. burgdorferi作为攻击接种物的体外杀伤分析和体内保护研究形成鲜明对比。针对莱姆病和其他媒介传播感染的疫苗效力评估应采用自然传播方式，而不应基于不依赖媒介传播感染的分类系统或检测方法。
